Issues
-
Cover Image
Cover Image
GUCY2C paracrine signaling plays an essential role in homeostatic mechanisms maintaining the crypt-villus axis in intestine. Radiation disrupts those mechanisms, inducing toxicity underlying the potentially lethal gastrointestinal (GI) syndrome. Expression of the GUYC2C receptor (green) and its paracrine hormone uroguanylin (red) was preserved in small intestine 48 hours following exposure of mice to toxic doses of radiation. These results suggest a role for the GUCY2C signaling axis in compensatory responses to intestinal radiation. Further, they support the utility of oral GUCY2C ligands to prevent and treat the radiation-induced GI syndrome. For details, see article by Li and colleagues on page 5095. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Perspective
Priority Report
Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Molecular and Cellular Pathobiology
NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas
Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1
FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2–Mediated Phosphorylation of CENP-A
Tumor and Stem Cell Biology
Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells
Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling
Therapeutics, Targets, and Chemical Biology
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells
Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy
Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors
Microenvironment and Immunology
CTLA4 Promotes Tyk2-STAT3–Dependent B-cell Oncogenicity
Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression
Integrated Systems and Technologies
Clinical Studies
Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers
Letter to the Editor
Retraction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.